- Home>
- Journal Watch
- >
- alendronate
Search for alendronate in all Journal Watch editions
Physician-authored summaries on the latest research on alendronate, editorials on alendronate, and perspectives on alendronate - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 103 results - Relevance
- Date
You searched for: alendronate
-
PPIs Might Decrease the Effectiveness of Alendronate to Prevent Fractures
Concurrent use of proton-pump inhibitors blunted the efficacy of the bisphosphonate in reducing risk for hip fractures in patients aged 70 and older.
CME Exam- Reviewing:
- Abrahamsen B et al., Arch Intern Med 2011 Jun 13; 171:998.
-
Alendronate and Atrial Fibrillation: Weighing Risks and Benefits
- June 12, 2008
- Wendy S. Biggs, MD
- Women's Health
Women who ever used alendronate were at higher risk for atrial fibrillation.- Reviewing:
- Heckbert SR et al., Arch Intern Med 2008 Apr 28; 168:826.
-
Alendronate and Risk for Atrial Fibrillation
Because of inconsistent results across several studies, it's still unclear whether oral bisphosphonates increase risk for atrial fibrillation.- Reviewing:
- Heckbert SR et al., Arch Intern Med 2008 Apr 28; 168:826.
-
Reversing Bone Loss with Alendronate in HIV-Infected Patients
- January 7, 2008
- Keith Henry, MD
- HIV/AIDS
In a randomized, placebo-controlled trial, weekly alendronate safely improved bone-mineral density among osteopenic HIV-infected patients receiving antiretroviral therapy.- Reviewing:
- McComsey GA et al., AIDS 2007 Nov 30; 21:2473.
-
Parathyroid Hormone vs. Alendronate for Steroid-Induced Osteoporosis
- November 27, 2007
- Allan S. Brett, MD
- General Medicine
Parathyroid hormone was associated with significantly greater increases in BMD and fewer vertebral fractures — but not nonvertebral fractures.- Reviewing:
- Saag KG et al., N Engl J Med 2007 Nov 15; 357:2028.
-
Alendronate’s Effect on Bone Loss in Men Treated with Hormonal Therapy for Prostate Cancer Free
- April 2, 2007
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Compared with placebo, an oral bisphosphonate significantly improved BMD and lessened bone turnover in men who were receiving ADT.- Reviewing:
- Greenspan SL et al., Ann Intern Med 2007 Mar 20; 146:416-24.
-
How Long to Take Alendronate for Osteoporosis? Free
- January 9, 2007
- Thomas L. Schwenk, MD
- General Medicine
Women at low risk for fracture after 5 years may be able to take a break.- Reviewing:
- Black DM et al., JAMA 2006 Dec 27; 296:2927-38.
-
Alendronate for Bone Loss Associated with Primary Biliary Cirrhosis
- October 25, 2005
- Atif Zaman, MD, MPH
- Gastroenterology
Decreased bone mass is common among patients with primary biliary cirrhosis (PBC) and can lead to devastating complications in the pre- and post-transplant setting. The . . .- Reviewing:
- Zein CO et al., Hepatology 2005 Oct; 42:762-71.
-
Alendronate for Osteopenia: Often Not Worth It
Some professional organizations recommend drug therapy for osteopenia, but the absolute benefit is very small, even for postmenopausal women who are nearly osteoporotic (Journal . . .- Reviewing:
- Schousboe JT et al., Ann Intern Med 2005 May 3; 142:734-41. McClung MR., Ann Intern Med 2005 May 3; 142:796-7.
-
Effect of Alendronate in Women with Osteopenia
- March 25, 2005
- Allan S. Brett, MD
- General Medicine
Alendronate (Fosamax) reduces fracture rates among women with osteoporosis, usually defined as bone mineral density T-scores lower than –2.5. However, the benefit of alendronate in . . .- Reviewing:
- Quandt SA et al., Mayo Clin Proc 2005 Mar; 80:343-9.
-
Alendronate for HIV-Associated Osteoporosis
- March 21, 2005
- Keith Henry, MD
- HIV/AIDS
Alendronate therapy showed benefit for treatment of HIV-associated osteoporosis in this open-label, randomized, pilot study.- Reviewing:
- Negredo E et al., AIDS 2005 Feb 18; 19:343-5.
-
Use of Alendronate Associated with Near Doubling of Atrial Fibrillation Risk Free
- April 29, 2008
- Physician's First Watch
Older women who use the osteoporosis drug alendronate may be at increased risk for atrial fibrillation (AF), reports Archives of Internal Medicine. Researchers at a... -
Benefits and Risks of Long-Term Alendronate Free
- December 28, 2007
- Anthony L. Komaroff, MD
- General Medicine
The FLEX study results help us determine for whom long-term alendronate therapy is beneficial. -
Stopping Alendronate After 5 Years Seems Safe for Most Women Free
- December 27, 2006
- Physician's First Watch
Women who stopped taking alendronate appear after 5 years to maintain bone mineral density compared with those who continue taking the drug, researchers report in... -
Atypical Fractures in Long-Term Bisphosphonate Users
- December 15, 2009
- Allan S. Brett, MD
- General Medicine
A small subgroup of women might be susceptible.- Reviewing:
- Capeci CM and Tejwani NC., J Bone Joint Surg Am 2009 Nov; 91:2556. Lenart BA et al., Osteoporos Int 2009 Aug; 20:1353.
-
Biologic Therapy Apparently More Effective Than Oral Therapy for Glucocorticoid-Associated Osteoporosis
- November 14, 2007
- Jeffrey P. Callen, MD
- Dermatology
Teriparatide was associated with greater bone density and fewer vertebral fractures in corticosteroid recipients, but the therapy is costly.- Reviewing:
- Saag KG et al., N Engl J Med 2007 Nov 15; 357:2028.
-
Five Years of Fosamax: Enough of a Good Thing?
- February 15, 2007
- Wendy S. Biggs, MD
- Women's Health
For many women, stopping alendronate after 5 years did not negatively affect BMD or fracture risk.- Reviewing:
- Black DM et al., JAMA 2006 Dec 27; 296:2927-38. Colón-Emeric CS., JAMA 2006 Dec 27; 296:2968-9.
-
Bisphosphonate Is Best to Prevent Corticosteroid-Induced Osteoporosis Free
- October 5, 2006
- Andrew M. Kaunitz, MD
- Women's Health
For patients taking corticosteroids, alendronate is more effective than alfacalcidol at preserving bone mineral density.- Reviewing:
- de Nijs RN et al., N Engl J Med 2006 Aug 17; 355:675-84.
-
PTH for Osteoporosis: Learning More
- September 20, 2005
- Andrew M. Kaunitz, MD
- Women's Health
In two recent NIH-supported clinical trials, investigators examined how to best use parathyroid hormone (PTH) in treating postmenopausal osteoporotic women.- Reviewing:
- Black DM et al., N Engl J Med 2005 Aug 11; 353:555-65. Cosman F et al., N Engl J Med 2005 Aug 11; 353:566-75.
-
Is Long-Term Bisphosphonate Therapy Safe?
- April 5, 2005
- Allan S. Brett, MD
- General Medicine
In a case series, long-term alendronate use was associated with reduced rates of bone formation and inadequate fracture healing.
Audio Interview- Reviewing:
- Odvina CV et al., J Clin Endocrinol Metab 2005 Mar; 90:1294-301. Ott SM., J Clin Endocrinol Metab 2005 Mar; 90:1897-9.
Sort by:
Items 1 to 20 of 103 results - Relevance
- Date
